pomalidomide has been researched along with arry 520 in 3 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (arry 520) | Trials (arry 520) | Recent Studies (post-2010) (arry 520) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 26 | 6 | 22 |
| Protein | Taxonomy | pomalidomide (IC50) | arry 520 (IC50) |
|---|---|---|---|
| Kinesin-like protein KIF11 | Homo sapiens (human) | 0.009 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
| Algarín, EM; Corchete, LA; Díaz-Rodriguez, E; Díaz-Tejedor, A; Garayoa, M; González-Méndez, L; Gutiérrez, NC; Hernández-García, S; López-Iglesias, AA; Martín-Sánchez, M; Mateos, MV; Misiewicz-Krzeminska, I; Mogollón, P; Ocio, EM; Paíno, T; San-Segundo, L; Tunquist, B | 1 |
| Bladé, J; Cejalvo, MJ; de Arriba, F; de la Rubia, J; Dourdil, MV; García-Malo, MD; García-Mateo, A; García-Sanz, R; Lahuerta, JJ; Martín-Sánchez, J; Martínez-López, J; Mateos, MV; Motlló, C; Ocio, EM; Oriol, A; Rodríguez-Otero, P; San-Miguel, JF | 1 |
1 review(s) available for pomalidomide and arry 520
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |
1 trial(s) available for pomalidomide and arry 520
| Article | Year |
|---|---|
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Kinesins; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Orosomucoid; Spain; Thalidomide; Thiadiazoles; Treatment Outcome | 2021 |
1 other study(ies) available for pomalidomide and arry 520
| Article | Year |
|---|---|
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cells, Cultured; Dexamethasone; Drug Synergism; Humans; Kinesins; Mice; Multiple Myeloma; Thalidomide; Thiadiazoles; Treatment Outcome | 2017 |